Drugs / Telpegfilgrastim
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06924385 | Apr 2025 → Jan 2026 | preeclampsia | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06893796 | Mar → May 2025 | preeclampsia | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06926751 | Jun 2025 → Apr 2027 expected | cancer, neutropenia | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06857292 | Dec 2024 → Dec 2025 overdue | neutropenia | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04466137 | Oct 2020 → Jun 2021 | neoplasm | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telpegfilgrastim | “This study evaluated the efficacy and safety of telpegfilgrastim, a novel Y-shaped PEG-rhG-CSF, for CIN prophylaxis in patients with non-small cell lung cancer (NSCLC).” PMID 40098083 ↗ Mar 2025 |
| Modality | Protein / enzyme biologic | “This study evaluated the efficacy and safety of telpegfilgrastim, a novel Y-shaped PEG-rhG-CSF, for CIN prophylaxis in patients with non-small cell lung cancer (NSCLC).” PMID 40098083 ↗ Mar 2025 |
| Route | Subcutaneous | “single s.c. at day 3 of each cycles” NCT04466137 ↗ |